What is Cutaneous Leishmaniasis Drugs?
Cutaneous leishmaniasis is a parasitic disease. It is spread by the female sandfly, which occurs in the new world and the old world. The drugs approved for cutaneous leishmaniasis treatment include fluconazole, tablet azole antifungals-systemic, Diflucan, Diflucan tablet azole antifungals-systemic, impavido, miltefosine capsule, pentam 300 solution, reconstituted, off and pentamidine 300 mg solution for injection antiprotozoal agents are.
Global Cutaneous Leishmaniasis Drugs Market Outlook
About 95% of cutaneous leishmaniasis cases occur in the Americas, the Mediterranean Basin, the Middle East, and Central Asia. In 2017 over 95% of new cutaneous leishmaniasis cases occurred in six countries: Brazil, Colombia, Afghanistan, Algeria, Iran, Iraq, and the Syrian Arab Republic. According to the World Health Organization, it is anticipated that between 600 000 to 1 million new cases arise worldwide yearly.
Cutaneous leishmaniasis cases have increased intensely in Syria and neighbouring countries due to the conflict-related displacement of Syrians. Advancement in drug therapies to provide a new treatment for cutaneous leishmaniasis. The current strategy is to control this disease mainly based on chemotherapy, presently used therapies against cutaneous leishmaniasis lead to complete cure. However, they associate with many limitations, efficacy remains hindered by the patient's age and immune system.
Lack of awareness, high cost of treatment and prolong treatment span hinders the growth of the market. World Health Organization (WHO) considers leishmaniasis to be one of the main neglected diseases in the world, affecting mostly the poor population of underdeveloped and developing countries.
Global Cutaneous Leishmaniasis Drugs Market Competitive Landscape
The "Global Cutaneous Leishmaniasis Drugs Market" study report will provide a valuable insight with an emphasis on global market including some of the major players such as GlaxoSmithKline, Novartis, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Albert David, Profounda, Knight Therapeutics and Johnson & Johnson. Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis.
Customization of the Report
• In case of any queries or customization requirements please connect with our sales team, who will ensure that your requirements are met.
1. INTRODUCTION OF GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET
1.1. Overview of the Market
1.2. Scope of Report
1.3. Assumptions
2. EXECUTIVE SUMMARY
3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
3.1. Data Mining
3.2. Validation
3.3. Primary Interviews
3.4. List of Data Sources
4. GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET OUTLOOK
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Porters Five Force Model
4.4. Value Chain Analysis
5. GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE
5.1. Overview
5.2. Pentavalent Antimonials
5.3. Antifungal Drugs
5.4. Anti-Leishmanial/Antimicrobial Drugs
6. GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.2. Hospitals Pharmacies
6.3. Retail Pharmacies
6.4. Online Pharmacies
7. GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY GEOGRAPHY
7.1. Overview
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.2.3. Mexico
7.3. Europe
7.3.1. Germany
7.3.2. U.K.
7.3.3. France
7.3.4. Rest of Europe
7.4. Asia Pacific
7.4.1. China
7.4.2. Japan
7.4.3. India
7.4.4. Rest of Asia Pacific
7.5. Rest of the World
7.5.1. Latin America
7.5.2. Middle East & Africa
8. GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET COMPETITIVE LANDSCAPE
8.1. Overview
8.2. Company Market Ranking
8.3. Key Development Strategies
9. COMPANY PROFILES
9.1. GlaxoSmithKline
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments
9.2. Novartis
9.2.1. Overview
9.2.2. Financial Performance
9.2.3. Product Outlook
9.2.4. Key Developments
9.3. Sanofi
9.3.1. Overview
9.3.2. Financial Performance
9.3.3. Product Outlook
9.3.4. Key Developments
9.4. Gilead Sciences
9.4.1. Overview
9.4.2. Financial Performance
9.4.3. Product Outlook
9.4.4. Key Developments
9.5. Bristol-Myers Squibb
9.5.1. Overview
9.5.2. Financial Performance
9.5.3. Product Outlook
9.5.4. Key Developments
9.6. Albert David
9.6.1. Overview
9.6.2. Financial Performance
9.6.3. Product Outlook
9.6.4. Key Developments
9.7. Profounda
9.7.1. Overview
9.7.2. Financial Performance
9.7.3. Product Outlook
9.7.4. Key Developments
9.8. Knight Therapeutics
9.8.1. Overview
9.8.2. Financial Performance
9.8.3. Product Outlook
9.8.4. Key Developments
9.9. Johnson & Johnson
9.9.1. Overview
9.9.2. Financial Performance
9.9.3. Product Outlook
9.9.4. Key Developments
10. Appendix
10.1. Related Reports
Executive Summary
Azoth Analytics has released a research report titled "Global IgG Mediated Autoimmune Diseases Biologic Drugs Market (2024 Edition)" which provides a complete analysis of the Global IgG Mediated Autoimmune Diseases Biologic Drugs industry in terms of market segmentatio...
Executive Summary
Azoth Analytics has released a research report titled "Global Antibiotic Drugs Market (2024 Edition)" which provides a complete analysis of the global Antibiotic Drugs industry in terms of market segmentation By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoro...
Overview of the Global Sex Hormone Drugs Market:
The report discusses everything a marketer requires before investing in the global Sex Hormone Drugs Market during the forecast period 2023-2030. It provides detailed...
Executive Summary
Azoth Analytics has released a research report titled "Incretin Based Drugs Market (2023 Edition)" which provides a complete analysis of the global Incretin Based Drugs industry in terms of market segmentation By Drug Type (Glucagon-like Peptide-1 Receptor Agonists, Di...
Overview of the Global Microecological Drugs Market :
The report discusses everything a marketer requires before investing in the global Microecological Drugs Market during the forecast period 2023-2030. It provide...
Overview of the Global Biosynthesis Peptide Drugs Market:
The report discusses everything a marketer requires before investing in the global Biosynthesis Peptide Drugs Market during the forecast period 2023-2030. It...
Overview of the Global Chemical Synthesis Peptide Drugs Market:
The report discusses everything a marketer requires before investing in the global Chemical Synthesis Peptide Drugs Market during the forecast period 2...
Description
The global veterinary dermatology drugs market exhibits positive growth prospects, forecast to expand at a CAGR of 5.4% between 2023 and 2029 to reach USD 8.08 billion in value. Veterinary dermatology focuses on treating skin diseases and disorders in animal patients, covering both...
Overview of the Global Drug Rehabilitation Drugs Market :
The report discusses everything a marketer requires before investing in the global Drug Rehabilitation Drugs Market during the forecast period 2023-2030. It...
Overview of the Global Rosuvastatin Drugs Market:
The report discusses everything a marketer requires before investing in the global Rosuvastatin Drugs Market during the forecast period 2023-2030. It provides detail...